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Abstract: We designed an experimental setup to charac-
terize the thrombogenic potential associated with blood
recirculating devices (BRDs) used in extracorporeal circu-
lation (ECC). Our methodology relies on in vitro flow loop
platelet recirculation experiments combined with the
modified-prothrombinase platelet activity state (PAS)
assay to quantify the bulk thrombin production rate of
circulated platelets, which correlates to the platelet activa-
tion (PA) level. The method was applied to a commercial
neonatal hollow fiber membrane oxygenator. In analogous
hemodynamic environment, we compared the PA level
resulting from multiple passes of platelets within devices
provided with phosphorylcholine (PC)-coated and
noncoated (NC) fibers to account for flow-related
mechanical factors (i.e., fluid-induced shear stress)
together with surface contact activation phenomena. We
report for the first time that PAS assay is not significantly
sensitive to the effect of material coating under clinically
pertinent flow conditions (500 mL/min), while providing
straightforward information on shear-mediated PA
dynamics in ECC devices. Being that the latter is intimately
dependent on local flow dynamics, according to our results,
the rate of thrombin production as measured by the
PAS assay is a valuable biochemical marker of the
selective contribution of PA in BRDs induced by device
design features. Thus, we recommend the use of PAS
assay as a means of evaluating the effect of modification
of specific device geometrical features and/or different
design solutions for developing ECC devices
providing flow conditions with reduced thrombogenic
impact. Key Words: Platelet activation—Blood
recirculating devices—Shear- and contact-associated
thrombogenicity—Extracorporeal circulation.
Open heart surgery involving cardiopulmonary
bypass (CPB) represents a highly thrombogenic clini-
cal environment (1). The extracorporeal circulation
(ECC) regimen induces marked abnormalities of
hemostasis, a potentially fatal complication when
associated with congenital and/or acquired coagula-
tion disorders (2). Thromboembolic events are pri-
marily caused by the combination of two effects
which contribute in enhancing platelet activation
(PA) leading to thrombus formation: (i) the
mechanical contribution upon the flowing corpuscu-
lar blood elements, and (ii) the contact of blood cells
with the nonendothelial surfaces of the ECC circuit
tubing and of the blood recirculating devices (BRDs,
e.g., blood oxygenator, heat exchanger, arterial filter,
etc.) (1,3). Mechanical solicitation is due to the syn-
ergistic action offered by the propelling devices (the
pump) and the nonphysiologic flow conditions
causing abnormal shear stress patterns within the
ECC circuit and the BRD geometry. In particular,
PA in BRDs is considered as one of the major pre-
cursors of the onset of thrombosis and thromboem-
bolism during the surgery. The risk of PA is not
totally eliminated by administering antithrombotic
drugs, which, in turn, may induce further complica-
tions such as iatrogenic hemorrhage and postopera-
tive bleeding vulnerability (4). So far, the problem of
thrombosis during CPB remains a concern even in
the presence of surface modification/coating strate-
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gies (5), suggesting that flow-related phenomena,
that is, the hemodynamic-related shear stress pat-
terns experienced by platelets within specific device
geometrical features, prevail in triggering PA.
However, at present, there is a lack of studies inves-
tigating the pro-coagulant properties of platelets
induced by flow through these devices, and the defi-
nition of a systematic strategy to optimize the design
of BRDs, that is, to reduce or eliminate flow condi-
tions that cause PA, still needs to be addressed.
Recently, research studies examining the impact of
implantable mechanical circulatory support (MCS)
devices on PA and thrombosis led to the develop-
ment of the modified prothrombinase platelet activ-
ity state (PAS) assay. The PAS assay is a laboratory
method able to measure the near real-time rate of
formation of thrombin—a universal thrombogenic
marker—by activated platelets and to correlate with
their activation level (6). The test is performed with
gel-filtered platelets (GFPs, i.e., platelets deprived of
plasma proteins), and the assay makes use of
acetylated prothrombin (Ac-FIIa) as the thrombin
substrate (7). The PAS assay allows measuring the
prothrombotic tendency of activated platelets, that
is, the platelet procoagulant activity, by detecting the
thrombin production rate of activated platelets,
without inducing aggregation or clot formation
during the test. Mechanisms leading to platelet
aggregation are precluded during the test, mainly due
to the removal of plasma coagulation factors (medi-
ating aggregation in whole blood) from GFP prepa-
rations (7). Furthermore, Ac-FIIa, while retaining
the ability to produce thrombin upon activation by
GFP-bound prothrombinase complex, is character-
ized by low (<0.1%) clotting activity (7). Moreover,
the thrombin produced by Ac-FIIa is inactive on
fibrinogen (7) and thus cannot mediate the conver-
sion of fibrinogen to fibrin. In addition, the use of
Ac-FIIa allows inhibiting the physiologic thrombin-
mediated positive feedback on PA. In detail, the
thrombin produced by the conversion of Ac-FIIa
does not feed back on the factor Xa (FXa) complex
to further activate platelets (7). Hence, with PAS
assay, the dose- and time-PA dynamics can be char-
acterized, in response to differing levels (i.e., varying
the dose and/or the exposure time) of the agonist,
ensuring a one-to-one relationship between the
inducer and the actual level of PA, which is propor-
tional to the thrombin production rate.
The PAS assay has been utilized extensively for
the in vitro characterization of shear-dependent PA
in MCS devices, such as prosthetic heart valves
(8–13), ventricular assist devices (6,14,15), and
the total artificial heart (16,17), where the
nonphysiological blood flow patterns (i.e., pulsatility,
eddy formation, turbulences, rapid flow acceleration/
deceleration phase, etc.) predominate the platelet
response. The PAS assay has been exploited through
two different approaches. It has been used as the final
step of an advanced design methodology, known as
device thrombogenicity emulation (DTE) (18–20).
This approach couples in silico analysis, to extract
device-specific flow conditions in the numerical
virtual domain, with in vitro experiments; specifi-
cally, selected most critical shear stress patterns are
replicated on platelet samples through an experimen-
tal apparatus, named hemodynamic shearing device
(19), emulating the predicted flow conditions; finally,
the related thrombogenic potential is quantified
through the PAS assay. The DTE is a straightforward
process to optimize the thrombogenic performance
of devices by estimating the effects of modifications
of specific design parameters in terms of device-
related hemodynamics. However, such an approach
cannot account for the whole fluid dynamics but can
estimate the potential PA on selected platelet trajec-
tories; as a matter of fact, it can be extremely useful
in the preliminary phase of BRD design. It is worth
noticing that it neglects the contact-associated PA.
Alternatively, the PAS assay has been used for char-
acterizing the dynamics of PA within flow loop
systems, where platelets are recirculated within
physical prototypes of the investigated devices and
thrombogenicity is measured in timed samples
extracted from the recirculation loop. When used in
combination with flow loop systems, the PAS assay
becomes extremely useful in an advanced stage of
BRD design, providing an accurate assessment of the
PA device potential. In fact, it allows to comprehen-
sively characterize the hemodynamic-related
thrombogenic potential of the device. Moreover, it
accounts, in principle, for both PA mechanisms,
including contact-associated PA, which could be par-
ticularly critical in BRDs, such as oxygenators, which
are characterized by considerable surface area and
higher platelet residence time with respect to MCS.
With this work, we aimed at investigating the
potential of extending the use of PAS assay to com-
prehensively characterize PA in BRDs that are used
in ECC procedures. To this purpose, an experimental
platform was developed to circulate platelets within a
commercial hollow fiber oxygenator and to quantify
the dynamics of PA via the PAS assay. Flow loop
experiments were performed replicating clinical-like
perfusion conditions, and the proposed methodology
was applied to devices with phosphorylcholine-
coated (PC) fibers and non-coated (NC) devices. In
this way, we tested the capability of the PAS assay (i)
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to quantify the shear-induced activation of platelets
in ECC devices, where shear loads are mainly deter-
mined by flow through a fiber mat, and (ii) to evalu-
ate at what extent the PAS assay is sensitive to the
contribution offered by platelet surface contact
interactions. This work represents a first step toward
the establishment of a laboratory platform able
to predict and prospectively limit the impact of
thrombogenicity associated to ECC practice.
MATERIALS AND METHODS
The hollow fiber blood oxygenator
The Dideco Kids D100 neonatal perfusion support
system (Sorin Group Italia S.r.l., Mirandola, Italy) was
used in our experimental campaign. The device has a
static priming volume of 31 mL and is equipped with:
(i) a microporous hollow fiber (polypropylene) bundle
oxygenator (OXY) characterized by a 0.22-m2 mem-
brane surface area for gas transfer, and (ii) a metal coil
(stainless steel) heat exchanger (HE) with a 0.03-m2
surface area to set and control the patient’s blood tem-
perature during the surgery. In the device, the blood
circumferential flow path is established (21).
Preparation of platelet samples
Whole blood (250 mL) was drawn through veni-
puncture from living adult ovine, collected into a
blood bag (TERUFLEX, Terumo Corporation,
Tokyo, Japan) containing 35 mL of citrate phosphate
dextrose adenine (CPDA-1) as anticoagulant and
transferred to the laboratory. Purified GFPs were
prepared from whole blood as described in Sheriff et
al. (6) (Fig. 1) and diluted to a standard concentra-
tion of 20 000 platelets/μL in a HEPES-modified
Ca2+-free Tyrode’s buffer (Platelet Buffer) contain-
ing 0.1% fatty acid-free bovine serum albumin, with
3 mM Ca2+ added 10 min prior to experiments (7,22).
Equilibrated GFPs were maintained with gentle agi-
tation at room temperature and used for flow loop
experiments within 6 h of gel filtration.
Flow loop circulation setup
An experimental setup for flow loop GFP circula-
tion experiments was designed (Fig. 2) including (i) a
50-mL Falcon tube (PBI, VWR International PBI
S.r.l., Milan, Italy) serving as GFP reservoir
immersed into a water-bath (VWB 6, VWR Interna-
tional) to set the desired GFP temperature (37°C)
during the test; (ii) a roller pump (Stockert-Shiley
10-10-00, Stockert GmbH, Freiburg, Germany) to set
the desired GFP flow perfusion rate (Q); (iii) a flow
meter (HT110, Transonic Systems Inc., Ithaca, NY,
USA) equipped with a clamp-on flow probe (H6XL,
Transonic); and (iv) two pressure sensors (PRESS-S-
000, PendoTECH, Princeton, NJ, USA) to monitor
the Q and the pressure drop (ΔP) across the OXY,
respectively; Q and ΔP were continuously monitored
during the test and acquired via an I/O hardware and
a custom-made software interface (DAQcard-6036E
and LabView, National Instruments, Austin, TX,
USA). The setup had a total priming volume of
95 mL (Kids D100 [31 mL] + hydraulic circuit
[57 mL] + GFP volume-reservoir [7 mL]). In Table 1,
dimensions and materials of the fluidic circuit com-
ponents are summarized. For each experiment, a new
hydraulic circuit was used.
Flow loop experiments
In Fig. 3, a schematic of the circulation flow loop is
provided. After the hydraulic circuit was gently filled
with GFP and accurately debubbled, the pump was
operated and GFP circulated for 120 min, which cor-
responded to more than 600 fluid passes through the
device, on average (Table 2). A Q equal to 500 mL/
min was set, corresponding to the average value of
the operating range recommended by the manufac-
turer for the Kids D100 (23). In the performed
experiments, the HE was not supplied with heating
fluid, and no gas was supplied through the gas inlet
port of the OXY module, so as to prevent heat and
gas exchange phenomena to influence the platelet
response. At pre-determined time-steps (Table 2)
FIG. 1. Schematic of the procedure for GFP extraction: whole blood was centrifuged (500 × g for 15 min) to obtain platelet-rich plasma
(PRP); PRP was isolated from red blood cells and gel-filtered through a column of Sepharose 2B (GE-Healthcare Life Sciences) to
separate plasma proteins from collected gel-filtered platelets (GFP).
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GFP samples were taken and assayed for PA via the
PAS assay; a disposable 1-mL syringe with an 18G ×
1/2″ needle (Terumo Corporation) connected to a
stopper connector (CareFusion Ltd., Basingstoke,
UK) was used to access flowing GFP (Fig. 3). For
each GFP sampling, a new syringe was used.
A total number (N) of eight devices were tested,
comparing the results obtained with PC fibers (PC,
N = 4) and NC devices (NC, N = 4). Each test was
conducted with GFP from individual blood donor.
Analysis of PA
At each time step (see Table 2), 200 μL of circulat-
ing GFP was taken from the circuit, and the resulting
platelet activation state (PAS) was measured as
follows: from each sample, a 100-μL tube containing
(final concentrations) 5000 platelets/μL, 200 nM
Ac-FIIa, 5 mM Ca2+, and 100 pM FXa was incubated
at 37°C for 10 min; then, a 10-μL sample was assayed
for thrombin generation using 0.3 mM Chromozym-
TH (Tosyl-Gly-Pro-Arg-4-nitranilide acetate, Roche
Life Science, Milano, Italy) as the thrombin-specific
chromogenic peptide substrate in a 96-wells
microplate reader (Multiskan GO, Thermo Fisher
Scientific, Inc., Waltham, MA, USA). Kinetic absor-
bance readings were performed at room temperature
at 405-nm wavelength for 8 min (6). The PAS value
was calculated as the slope of the linear fitting of the
absorbance time data points, over the 8-min kinetic
reading. PAS values were normalized against those
obtained by sonicating uncirculated platelets with a
microprobe sonicator (HD 2070 Sonoplus, Bandelin
FIG. 2. (A) The experimental setup used for
flow loop GFP circulation experiments:
platelets were circulated for 120 min at a
500-mL/min flow rate; a GFP sampling port
was provided downstream of the Kids D100
(red arrow): sampled platelets were assayed
via the PAS assay. (B) The metallic heat
exchanger (HE) and the polymeric hollow
fiber bundle oxygenator (OXY) modules
comprising the Kids D100 neonatal
perfusion system. (C) The Falcon tube
serving as GFP reservoir.
TABLE 1. Dimensions and materials of the elements composing the hydraulic circuit used for GFP flow loop
circulation experiments
Element ID (inches) Length (cm) Material
Pump inset 1/4 55 Raumedic ECC—Silicone
Upstream tubing for hydraulic circuit* 1/4 65 Dideco XS class VI—PVC
Downstream tubing for hydraulic circuit† 3/16 40 Dideco XS class VI—PVC
Element ID (inches) n Material
Tube-to-tube connector 1/4–1/4 2 PC
Tube-to-tube connector 1/4–3/16 2 PC
*Upstream tubing connects the reservoir to the OXY inflow; †downstream tubing connects the OXY outflow to the reservoir. ID, internal
diameter; n, number of elements; PC, polycarbonate; PVC, polyvinylchloride.
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Electronic GmbH& Co. KG, Berlin, Germany). The
sonication step is meant to yield platelets with
maximal prothrombinase activity; thus, normalized
PAS values (expressed in percentage, PAS [%]) rep-
resent the bulk activity as a fraction of the thrombin
generation rate of sonicated platelets (100%) (22).
Sonication conditions (10 W for 15 s) were optimized
for ovine platelets starting from the protocol
reported in Schulz-Heik et al. (22) for human plate-
lets. For each test, uncirculated platelets were also
assayed, as the negative control. Change in PAS
(ΔPAS) was calculated over the duration of the cir-
culation experiments (0–120 min), and the platelet
activation rate (PAR) was quantified as the slope of
the linear fitting of the PAS versus circulation time
data points.
From each GFP sample, multiple
spectophtometric readings (n) were performed to
evaluate data consistency; in detail: (i) for circulated
platelets, at each time-point, two independent
100-μL tubes were incubated, which were then split
in two different microwells in the microplate reader,
giving a number of readings, n = 4; (ii) for sonicated
samples, two independent GFP samples were
sonicated, each incubated in two independent 100-μL
tubes and split in two different microwells (n = 4);
(iii) for blank samples, a 100-μL tube was read in
duplicate (n = 2) in the microplate reader.
Statistical analysis
Data of ΔP, ΔPAS, and PAR for the two groups
(PC and NC fiber devices) are presented as
mean ± standard deviation (SD). The Shapiro–Wilk
normality and F-test equality of variance tests were
used to evaluate that the data were normally distrib-
uted; accordingly, results were compared through
parametric Student’s t-test. A P value < 0.05 was
accepted as statistically significant.
RESULTS
The mean value of the ΔP across the OXY
remained constant for all the tested devices through-
out the whole 120-min duration of the recirculation
experiment: this evidence ensured that no undesir-
able fluid dynamic disturbances/anomalies affected
the flowing GFP. Moreover, with equal rotational
speed of the pump rotor (1.85 rpm) set to deliver the
GFP flow rate in the two sets of experiments, no
statistically significant differences were observed
comparing the ΔP of the PC versus NC devices
(43.3 ± 8.6 vs. 46.3 ± 5.9 mm Hg, P = 0.584). Those
data indicate that in all the experiments, platelets
were subjected to equivalent mechanical and fluid-
induced solicitation offered by the pump propelling
action and the streamflow within the hydraulic circuit
and the device.
To discriminate between device-specific PA in
response to the different surface membrane coating
FIG. 3. Schematic of the experimental
setup for GFP flow loop circulation experi-
ments with the Kids D100 perfusion system:
solid lines represent the hydraulic circuit
with the arrows indicating the direction of
flow; dashed lines indicate the electrical
connections between the flow and pressure
sensors and the I/O data acquisition system.
TABLE 2. Time points and corresponding number of
passes at which GFP was taken from the flow loop setup
and assayed via PAS assay
Time (min) 0* 10 20 30 60 90 120
# Passes 0* 53 105 158 316 474 632
*Indicates GFP sample taken after the circuit was filled and
debubbled, before operating the pump.
PLATELET ACTIVATION IN EXTRACORPOREAL CIRCULATION DEVICES 5
Artif Organs, Vol. ••, No. ••, 2016
characterizing PC and NC devices, in Fig. 4, we
report the results of PAS assay from the 120-min in
vitro circulation experiments. According to our data,
a linear evolution of PA with increasing circulation
time (i.e., number of passes) was observed for the
GFP recirculated in both PC and NC devices
(Fig. 4A). In addition, the comparison of PA
between PC and NC devices (Fig. 4B) revealed that
differences in ΔPAS and PAR were not significant
(ΔPASPC = 23.09 ± 9.66 vs. ΔPASNC = 23.11 ± 7.33,
P = 0.601; PARPC = 17.07 ± 4.85 vs. PARNC = 18.76 ±
5.97, P = 0.356), although interdonor variability had
a notable influence on statistical dispersion of the
data.
DISCUSSION
Thrombosis during CPB can be related to patient-
specific factors and/or insufficient anticoagulation
regimen. Nonetheless, thrombogenicity is potenti-
ated by the nonphysiologic hemodynamic regimen
associated to blood flow within medical BRDs (2,24).
Thus, a proper design of BRDs represents a key
factor to be thoroughly investigated. Current criteria
for the design of BRDs do not include the analysis of
their associated thrombogenic potential. Typically,
design specifications are focused on performance
optimization, such as minimization of pressure losses
and priming volumes, together with maximization of
gas and/or heat transfer efficiency (25,26). Flow-
induced blood trauma is almost exclusively studied
with respect to red blood cell damage (hemolysis).
Thrombogenicity tests are performed on animal
models for the preclinical evaluation of the device
performance. However, animal studies are costly and
time-consuming (24), and they are not compliant
with ethics principles and with recent guidelines,
which promote reducing the use of animals in
research and testing (27). Moreover, in the context of
a device’s route toward clinical application, animal
tests are typically performed at the late stage of the
device design process. Although dealing with design
changes (at any stage) in the design cycle is an inevi-
table reality for manufacturers, late stage design
modifications can cause massive delays to the
product design process and increment of manufactur-
ing costs. Further, in vivo models are not even able
to distinctively identify those specific design
features that are responsible for device-related
thrombogenicity. When preclinical results are not
FIG. 4. (A) Normalized PAS values of recir-
culated GFP are plotted for PC and NC
devices over the 120-min flow loop experi-
ments (mean ± SD; n = 4): dashed and solid
lines indicate the linear regression lines of
the PAS versus circulation time data points,
for the PC- and NC-devices, respectively;
different colors identify each of tested
devices (PC1-PC4 and NC1-NC-4). (B)
Comparison of calculated ΔPAS and PAR
between PC and NC devices (mean ± SD;
for each group N = 4 from independent
blood donor). Data were normally distrib-
uted (Shapiro–Wilk normality test: P = 0.519
and P = 0.859 for ΔPAS and PAR respec-
tively; F-test equality of variance: P = 0.757
and 0.756 for ΔPAS and PAR, respectively).
Student’s t-test revealed there is no statisti-
cally significant difference between the two
groups (ΔPAS: P = 0.601; PAR: P = 0.356).
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satisfactory, the general design of the device needs to
be revised and tested iteratively, without any specific
indication guiding the rational design optimization
aimed at the minimization of the device
thrombogenic potential.
In contrast, to date, different laboratory tech-
niques, such as platelet aggregation testing, exist to
estimate platelet function (28). Nevertheless, these
laboratory tests are affected by severe limitations
preventing these techniques to be widely accepted as
valuable, standardized, and recognized methods for
the thrombogenic optimization of BRDs. Major limi-
tations include their inability of evaluating the initia-
tion mechanism of PA, that is, to discriminate
between the influence of different agonists acting
concomitantly, as occurring in ECC devices
(mechanical and flow-induced solicitation together
with surface contact-associated activation). In addi-
tion, they largely look at biochemical endpoints of
PA rather than at its dynamics; thus, they are not
suited for the analysis of dose and time PA rate, for
characterizing recirculating ECC devices. These
assays are performed using whole blood and/or
platelet-rich plasma preparations as the platelet fluid
vector, where the physiologic thrombin-mediated
feedback activation mechanism further elevates the
level of PA induced by the device. As a result, they
are not reflective of the actual thrombogenic level of
a given device, preventing the possibility of compar-
ing the thrombogenic impact of different design solu-
tions. Flow cytometry may be also applied for the
study of PA dynamics using GFP preparations.
However, flow cytometry implies repeated sample
manipulation, required for fixation, antibody label-
ing, and washing, which may affect the accuracy of
the analysis. Moreover, fixative agents (formalde-
hyde or paraformaldehyde) have been reported to
potentially induce a decrease of the sample fluores-
cence intensity (29,30), as well as a time-dependent
modification of the PA level (31). Furthermore, flow
cytometry requires expensive reagents (antibodies)
and equipment (FACS) and highly specialized dedi-
cated personnel. In the prospective of overcoming
some of the limitations listed above and developing
reliable procedures for the experimental evaluation
of thrombogenicity in ECC medical devices, in this
work, we designed an in vitro methodology able to
characterize the dynamics of activation of platelets
within BRDs, in experimental clinical-like flow con-
ditions. Our investigation approach is based on the
use of the PAS assay as the “tool” for characterizing
PA dynamics. Notably, with the PAS assay, we can
separate the different contributions concomitantly
enhancing PA, selectively evaluate the flow-
associated contribution on GFP which is related to
the specific device geometry, and neglect all the other
factors influencing and mediating thrombus forma-
tion in whole blood (i.e., plasma coagulation factors,
thrombin-mediated PA feedback). As a result, the
PAS assay can be employed for comparative analysis
to identify a convenient design solution minimizing
the thrombogenic potential.
In detail, our work was directed toward a twofold
aim: (i) to test the efficacy of PAS assay to catch the
dynamics of shear-dependent PA in response to
repeated passes of platelets through a commercial
hollow fiber blood oxygenator, where hemodynamic
conditions are considerably different with respect to
the MCS devices previously studied in literature; and
(ii) to test the sensitivity of the PAS assay to surface
contact-associated PA, comparing the platelet
response induced by phosphorylcholine coating strat-
egy in an unaltered fluid dynamic environment.
Among the variety of BRDs used for ECC, a neo-
natal OXY was chosen for our experimental
campaign, even though it may not necessarily be the
most thrombogenic device. The use of a neonatal
perfusion system was dictated by the need to limit the
blood volume to be retrieved from animals (a rela-
tively large GFP volume is required for the flow
loop). Furthermore, our choice was justified in con-
sideration of the distinctive hemodynamics within
the device, where different disturbed flow patterns
arise, potentially eliciting PA, and of the consider-
able surface area and platelet residence time charac-
terizing the hollow fiber bundle, enabling the analysis
of the contact-induced platelet response. In fact, in
the relatively complex blood flow path within a
hollow fiber OXY device, flowing platelets are
exposed to: (i) secondary flows and recirculation/
stagnation areas, such as those due to the gradual
section reduction/enlargement of the inlet divergent
and outlet convergent conduits, respectively; (ii)
sudden changes of the velocity vectors (e.g., within
the upstream and downstream manifolds of the inlet
and outlet zones of the Kids D100) where the
streamflow is driven circumferentially toward the
hollow fiber bundle of the OXY module, and
the outlet section, respectively [23]; (iii) anisotropic
flow distribution across the array of the fiber bundle,
where nonnegligible shear stress occurs due to the
friction with the fiber walls, as reported in Pelosi et al.
(32). In addition, there is supporting evidence in lit-
erature that phosphorylcholine surface coating is
effective in protecting platelets from elevated activa-
tion during ECC (3,33–35). Thus, our experimental
layout (comparison of PC vs. NC devices) allowed us
to test the sensitivity of the assay to detect GFP-
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surface contact interactions under flow, in a conve-
nient clinically pertinent in vitro setting.
According to our results, a linear dependency of
the PA level with respect to the circulation time was
detected, over a 120-min circulation flow loop. Those
data provide evidence that the PAS assay is effective
in detecting the dynamic of activation of recirculating
platelets, as well as in quantifying even low changes
in PA level, as the ones we observed at increasing
number of passes. The linear dependency of PA with
increasing time of exposure we observed does not
support the platelet stimulation function defined by
Boreda et al. (36), its key feature being the prediction
that PA should vary linearly with shear stress but
nonlinearly (as a fractional power) with time of expo-
sure. Nonetheless, our results are in fair agreement
with previous observations from GFP circulating
flow loop experiments in severely disturbed dynamic
flow conditions, as the ones generated in MCS (6,13),
as well as in in vitro stenotic tube-geometry systems
with lower PA potential (37).
No significant differences have emerged by com-
paring PC versusNCdevices, with comparable results
obtained for ΔPAS and PAR values. This represents
the most intriguing aspect of our results. In fact, our
data suggest that fluid shear-dependent contribution
predominates the platelet response under flow and
that, conversely, the effects of GFP-surface contact
interactions are not detected, even in the presence
of relevant surface area- and residence time-
characteristic devices. Similar observations have been
recently reported by Merkle and colleagues, which
described reduced deposition and adhesion of plate-
lets on nanofiber composites under shear conditions
with respect to static platelet incubation (38).
With material-surface interactions becoming not
critical, the experimental methodology we developed
allows focusing the evaluation of the device-induced
thrombogenicity on local flow conditions deriving
from specific device geometrical features, selectively.
As for the PA values we found, our results do not
directly correlate with in vivo clinical data (the
present study was not directed toward the clinical
characterization of the Kids D100). Firstly, our
experiments were conducted with platelets of animal
(ovine) origin. Although this choice was considered
to be a reliable experimental approach, considering
that pre-clinical trials of medical devices are typically
performed with animal blood, limited interspecies
differences emerged in terms of platelet thrombin
production rate. According to our sonication experi-
ments (data not shown), indeed, a prolonged expo-
sure time (15 s) was required to maximize the
prothrombinase activity of ovine platelets with
respect to human platelets (10 s [22]), suggesting a
relative different sensitivity to activation of platelets
of ovine origin.Our results are supported by the study
conducted by Tran and colleagues (39) who used the
PAS assay to compare the sensitivity of human and
ovine platelets to fluid shear stress, reporting few
differences in the ovine platelet response. Moreover,
our experiments do not account for the protective
activation mechanism offered by administered
antithrombotic drugs. In addition, our experiments
are not reflective of the response of physiological
whole blood, consisting of red and white blood cells
and plasma proteins offering a complementary
agonistic/antagonistic action on PA in vivo (40). In
contrast, the use of isolated platelets (GFP) and
the chemical modification of the prothrombin
(acetylation) allowedus to examine thedirect effect of
fluid shear stress on PA, avoiding platelet aggregation
and clot formation, and ensured that the thrombin
produced by activated platelets, while assayable, did
not further activate platelets. Lastly, clinical settings
would not typically imply a number of passes of the
patient blood through theKidsD100perfusion system
as high as 600 times, rather this was chosen as a
reasonable target value in our GFP experiments as a
means to amplify the detectionofPAdynamics via the
PAS assay in a 120-min experiment.
Those discrepancies may limit the translational
characteristic of our research. However, the pro-
posed methodology provides an immediate and
efficient in vitro approach for minimizing the shear-
induced activation of platelets in BRDs. Remark-
ably, our study signals significant possibilities for
the establishment of a reliable platform for the mea-
surement and minimization of the PA potential in in
vitro circulation models of cardiovascular ECC
devices, as well as of different classes of hollow fiber-
recirculating devices characterized by hemodynamic
conditions potentially eliciting PA and thrombosis,
such as blood detoxification systems and/or dialyzers.
CONCLUSIONS
This study shows that time-resolved activation of
platelets induced by hemodynamic shear stress can be
quantitatively assessed in blood recirculation device
circulation flow loop platforms through the platelet
activity state assay. It highlights that the PAS assay
selectively focuses on the cumulative effects of shear
stress and time of exposure on activation of platelets,
while neglecting the role of surface contact phenom-
ena. Accordingly, the PAS assay is a valuable and
effective tool to support the design optimization of
local flow dynamics in extracorporeal circulation
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devices in in vitro clinically pertinent perfusion con-
ditions. Our methodology can be applied at any stage
of the design optimization process, allowing charac-
terization of the flow-dependent PA of a given (even
not definitive) design solution, and comparing the
influence of modifications of specific geometrical fea-
tures conceived to reduce or eliminate the critical flow
conditions that are responsible for eliciting PA and
thrombosis. In contrast, in the clinical setting,
patient’s whole blood is recirculated during ECC,
implying that additional aspects of hemostasis and
thrombosis are involved, including surface contact
PA. In view of this, we intend the proposed method-
ology as complementary to standard tests aimed at
assessing the biocompatibility of materials used for
blood handling medical devices.
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